Skip to main content

Table 1 Overall dropout rate and main reasons for treatment discontinuation in RCT

From: Drop-out rate among patients treated with omalizumab for severe asthma: Literature review and real-life experience

Author [ref] N duration (months) Mean ± SD age, years M/F Ratio Drop-out rate (%) Patient decision (%) Lack of efficacy (%) Adverse events (%) Other Causes (%)
Busse et al. 2001 [16] 268 7 39.3 0.63 7.1 4.1 0.37 0.74 1.49
Soler et al. 2011 [23] 274 7 40.0 1.06 6.9 1.09 1.09 NR NR
Holgate et al. 2004 [21] 126 8 41.1 0.55 8.7 8.7 NR NR NR
Ayres et al. 2004 [19] 206 12 37.5 0.39 7.3 NR NR 7.3 NR
Vignola et al. 2004 [24] 209 7 38.3 ± 14.7 0.92 8.1 8.1 NR NR NR
Humbert et al 2005 [22] 209 7 43.4 ± 13.3 0.48 12.2 NR NR 4.5 NR
Hanania et al. 2011 [20] 427 12 43.7 ± 14.3 0.63 19.4 11.00 NR 3.74 4.68
  1. F female, M male, NR not reported, RCT randomized controlled trials, SD standard deviation